%0 Journal Article
%T 卡双平治疗新诊断2型糖尿病患者的疗效及安全性研究<br>Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy in Treating Patients with Newly Diagnosed T2DM
%A 雷莎
%A 周筠
%J Advances in Clinical Medicine
%P 1869-1873
%@ 2161-8720
%D 2020
%I Hans Publishing
%R 10.12677/ACM.2020.109281
%X <div style=\"text-align:justify;\">
	目的：观察卡双平(吡格列酮二甲双胍)治疗新诊断2型糖尿病(type 2 diabetes mellitus, T2DM)患者的疗效及安全性。方法：选取35例新诊断的T2DM患者，观察卡双平治疗12周后糖化血红蛋白(hemoglobin A1c，HbA1c)及空腹血糖(fasting plasma glucose, FPG)的变化，明确药物的疗效及不良反应。结果：经过卡双平12周治疗后，新诊断的T2DM患者HbA1c及FPG水平明显下降(P &lt; 0.05)，而且没有严重不良反应发生(P &gt; 0.05)。结论：卡双平治疗新诊断的T2DM患者疗效确切，不良反应发生率低，可作为新诊断T2DM患者的治疗方案之一。<br />
Objective: To examine the efficacy and safety of pioglitazone/metformin fixed-dose combination therapy in a twice-daily regimen over 12 weeks treatment in newly diagnosed T2DM patients. Methods: 35 cases newly diagnosed T2DM patients were recruited. The changes of HbA1c, FPG and adverse events were evaluated at 12 weeks. Results: After 12 weeks treatment, HbA1c and FPG were significantly decreased compared with baseline. The pioglitazone/metformin fixed-dose combination was well tolerated with no unexpected findings in adverse events. Conclusions: The pioglitazone/metformin fixed-dose combination exhibits an excellent efficacy and safety for T2DM, which is a selection for those patients with newly diagnosed T2DM.
</div>
%K 2型糖尿病，吡格列酮二甲双胍，血糖，糖化血红蛋白<br>T2DM
%K Pioglitazone/Metformin Fixed-Dose Combination
%K Glycemic
%K HbA1c
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=37514